Granted Patent
B2
US 12,403,150 · App. 19/040,329 · Granted Sep 2, 2025
Tryptamine compositions for enhancing neurite outgrowth
Assignee:
TURTLE BEAR HOLDINGS, LLC
A61K31/661A61K9/08A61K31/05A61K31/352A61K31/4045A61K31/455A61K36/06A61K36/066A61K36/07A61K36/185A61K36/73A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
Claims (30)
1. A method for treating or ameliorating one or more symptoms of a serotonin (5-hydroxytryptamine, 5-HT) receptor disorder in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical dosage form comprising:
0.01 mg to 10 mg of psilocin, psilocybin, salts thereof, or combinations thereof; and
one or more pharmaceutically acceptable excipients selected from carriers, fillers, binders, disintegrants, preservatives, or antioxidants;
wherein the serotonin (5-hydroxytryptamine, 5-HT) receptor disorder comprises depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression, bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depressions, situational depression, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, attention deficit/hyperactivity disorder, substance abuse disorders or combinations thereof.
2. The method of claim 1 , wherein the pharmaceutical dosage form comprises 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin or psilocin.
3. The method of claim 1 , wherein the wherein the psilocin, psilocybin, salts thereof, or combinations thereof are:
(a) pure compounds;
(b) from mushroom species comprising psilocybin, psilocin, salts thereof, or combinations thereof; or
(c) from extracts of mushroom species comprising psilocybin, psilocin, salts thereof; combinations thereof.
4. The method of claim 1 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of niacin.
5. The method of claim 1 further comprising acidifying agents, alkalizing agents, antifoaming agents, sweetening agents, buffering agents, chelating agents, coating agents, emulsifying agents, solubilizing agents, flavoring agents, coloring agents, humectants, or a combination thereof.
6. The method of claim 1 , wherein the administration is at a regular interval until the subject in need thereof does not require administration.
7. The method of claim 1 , wherein the pharmaceutical dosage form is administered 1 to 6 times per day.
8. The method of claim 1 , wherein the psilocybin or psilocin bind to a neurotropin receptor.
9. The method of claim 1 , wherein the pharmaceutical dosage form releases one or more neurotropins.
10. The method of claim 1 , wherein the pharmaceutical dosage form enhances neuronal plasticity.
11. A method for treating or ameliorating one or more symptoms of a serotonin (5-hydroxytryptamine, 5-HT) receptor disorder in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical dosage form comprising:
0.1 mg to 10 mg of psilocin, psilocybin, salts thereof, or combinations thereof; and
one or more pharmaceutically acceptable excipients selected from carriers, fillers, binders, disintegrants, preservatives, or antioxidants;
wherein the serotonin (5-hydroxytryptamine, 5-HT) receptor disorder comprises depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression, bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depressions, situational depression, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, attention deficit/hyperactivity disorder, substance abuse disorders or combinations thereof.
12. The method of claim 11 , wherein the wherein the psilocin, psilocybin, salts thereof, or combinations thereof are:
(a) pure compounds;
(b) from mushroom species comprising psilocybin, psilocin, salts thereof, or combinations thereof; or
(c) from extracts of mushroom species comprising psilocybin, psilocin, salts thereof; combinations thereof.
13. The method of claim 11 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of niacin.
14. The method of claim 11 , further comprising acidifying agents, alkalizing agents, antifoaming agents, sweetening agents, buffering agents, chelating agents, coating agents, emulsifying agents, solubilizing agents, flavoring agents, coloring agents, humectants, or a combination thereof.
15. The method of claim 11 , wherein the administration is at a regular interval until the subject in need thereof does not require administration.
16. The method of claim 11 , wherein the pharmaceutical dosage form is administered 1 to 6 times per day.
17. The method of claim 11 , wherein the psilocybin or psilocin bind to a neurotropin receptor.
18. The method of claim 11 , wherein the pharmaceutical dosage form releases one or more neurotropins.
Continuity (6)
Provisional Application
63007482
· Apr 9, 2020
Provisional Application
62937536
· Nov 19, 2019
References Cited (167)
US 3075992A
· Hofmann et al.
· 1963
[cited by applicant]
US 3078214A
· Hofmann et al.
· 1963
[cited by applicant]
US 3192111A
· Hofmann et al.
· 1965
[cited by applicant]
US 20010008641A1
· Krotzer
· 2001
[cited by applicant]
US 20100028469A1
· Alberte et al.
· 2010
[cited by applicant]
US 20110206721A1
· Nair
· 2011
[cited by applicant]
US 20140220150A1
· Stamets
· 2014
[cited by applicant]
US 20150209306A1
· Bredesen et al.
· 2015
[cited by applicant]
US 20180021326A1
· Stamets
· 2018
[cited by applicant]
US 20180021405A1
· Hausman
· 2018
[cited by applicant]
US 20190142851A1
· Chadeayne
· 2019
[cited by applicant]
US 20190240293A1
· Weinstein
· 2019
[cited by applicant]
US 20220304980A1
· Arnold et al.
· 2022
[cited by applicant]
US 20230026731A1
· Kochinke et al.
· 2023
[cited by applicant]
WO 2005039546A2
· 2005
[cited by applicant]
WO 2006091988A1
· 2006
[cited by applicant]
WO 2008062983A1
· 2008
[cited by applicant]
WO 2014205250A1
· 2014
[cited by applicant]
WO 2016001922A1
· 2016
[cited by applicant]
WO 2016009021A1
· 2016
[cited by applicant]
WO 2018135943A1
· 2018
[cited by applicant]
WO 2020181194A1
· 2020
[cited by applicant]
WO 2021041407A1
· 2021
[cited by applicant]
WO 2021188812A1
· 2021
[cited by applicant]
WO 2022187973A1
· 2022
[cited by applicant]
Bartlett “Exploiting Chemical Diversity for Drug Discovery” Edited by Paul A Bartlett and Michael Entzeroth, The Royal Society of Chemistry, 2006, pp. 113-118.
[cited by examiner]
“Find ETDs Home » Thesis Resources » Find ETDs” Online: “https://ndltd.org/thesis-resources/find-etds/” Accessed Jan. 31, 2023.
[cited by examiner]
Irwin “ZINC—A Free Database of Commercially Available Compounds for Virtual Screening” J. Chem. Inf. Model. 2005, 45, 177-182.
[cited by examiner]
Kim “PubChem in 2021: new data content and improved web interfaces” Nucleic Acids Research, 2021, vol. 49, Database issue Published online Nov. 5, 2020.
[cited by examiner]
STN Registry/Zregistry (CAS Registrysm) Sep. 2016 2 pages.
[cited by examiner]
“Amount of niacin in mushrooms,” <http://dietandfitnesstoday.com/niacin-in-mushrooms.php> May 28, 2019.
[cited by applicant]
“Find ETDs Home » Thesis Resources» Find ETDs” Online: “https://ndltd.org/thesis-resources/find-etds/” Accessed Jan. 31, 2023 (7 pages).
[cited by applicant]
“Comorbid.” Mirriam-Webster.com Dictionary. Merriam-Webster. https://www.merriam-webster.com/dictionary/cobmorbid. Last updated Aug. 14, 2024 (6 pages).
[cited by applicant]
“Human Body Weight.” Wikipedia. https://en.wikipedia.org/wiki/Human_body_weight (17 pages).
[cited by applicant]
Beug et al., “Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A.”, J. Ethnopharmacology, 1982, vol. 5, No. 3, pp. 271-285.
[cited by applicant]
Blei et al., “Simultaneous Production of Psilocybin and a Cocktail of ß-Carboline Monoamine Oxidase Inhibitors in ‘Magic’ Mushrooms,” Chem. Eur. J., 2020, 26:729-734.
[cited by applicant]
Byock, I. “Taking psychedelics seriously.” Journal of palliative medicine 21.4 (2018): 417-421.
[cited by applicant]
Calabrese, F., et al. (2009). Neuronal plasticity: A link between stress and mood disorders. Psychoneuroendocrinology, 34 (Suppl 1), S208-S216.
[cited by applicant]
Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”, Lancet Psychiatry, vol. 3, 2016, pp. 619-627.
[cited by applicant]
Carhart-Harris, R. L., et al. “Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.” The British Journal of Psychiatry 200.3 (2012): 238-244.
[cited by applicant]
Carod-Artal, Hallucinogens in Pre-Columbian Mesoamerican Cultures Neurology, 2015, vol. 30, Issue 1, Jan.-Feb. 2015, pp. 42-49.
[cited by applicant]
Catlow et al., “Effects of psilocybin in hippocampal neurogenesis and extinction of trace fear conditioning,” Exp. Brain Res., 2013, 228:481-491.
[cited by applicant]
Chaiyasut et al., “Anti-hyperglycemic property of Hericium erinaceus—A Mini Review”, Asian Pac. J. Trop. Biomed., vol. 7, No. 11, 2017, pp. 1036-1040.
[cited by applicant]
Chong et al., “Therapeutic Potential of Hericium erinaceus for Depressive Disorder”, International Journal of Molecular Sciences, 2020, vol. 21, No. 1, 163.
[cited by applicant]
Chycho, “The Boundary Salvia divinorum, Fasting & Mushrooms—
[cited by applicant]
Davis et al., “Differential Immune Activating, Anti-Inflammatory, and Regenerative Properties of the Aqueous, Ethanol, and Solid Fractions of a Medicinal Mushroom Blend”, J. Inflammation Res., vol. 13, 2020, pp. 117-131.
[cited by applicant]
De la Fuente Revenga et al., “Neurogenic potential assessment and pharmacological characterization of 6-Methoxy-1,2,3,4-tetrahydro-ß-carboline (pinoline) and melatonin-pinoline hybrids”, ACS Chemical Neuroscience, 2015,…
[cited by applicant]
DMT-Nexus, “Known substance-interactions and their effects”, <https://wiki.dmt-nexus.me/Known-substance-interactions_and_their_effects>, 2013, 1 page.
[cited by applicant]
Drugs.com, “lovie . . . Taken for 1 to 6 months Jul. 12, 2018” Jul. 12, 2018; retrieved from Drugs.com comment. https://www.drugs.com/comments/niacin/for-depression.html, retrieved Jul. 12, 2018.
[cited by applicant]
Dunst, J et al. “Cytokines and chemokines in cerebral malaria pathogenesis.” Frontiers in cellular and infection microbiology 7 (2017): 324.
[cited by applicant]
Erowid, “Psilocybin, Psilocin, and Magic Mushroom Dosage” Jan. 18, 2013; retrieved from Erowid; retrieved from Web Archives. https://web.archive.org/web/20130118160500/https:/erowid.org/plants/mushrooms/mushrooms dose.s…
[cited by applicant]
European Patent Office, Extended European Search Report for Application No. 20890349.2, dated Mar. 18, 2024 (16 pages).
[cited by applicant]
Fadiman, “Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration”, J Psychoactive Drugs, 2019, vol. 51, No. 2, pp. 118-122.
[cited by applicant]
Fadiman, J. “Microdose research: Without approvals, control groups, double-blinds, staff or funding.” Psychedelic Press 15 (2016): 53-59.
[cited by applicant]
Ferreira, et al., “Ketamine can be produced by Pochonia chlamydosporia: an old molecule and a new anthelmintic?,” Parasites & Vectors, 2020, 13 (527): 1-9.
[cited by applicant]
Fink, C.C. et al. Selective Regulation of Neurite Extension and Synapse Formation by the ß but not the α Isoform of CaMKII. Neuron (2003)39 (2): 283-297.
[cited by applicant]
Flannagan and Nichols, Psychedelics as anti-inflammatory agents, Int. Rev. Psychiatry, 2018, 30(4): 363-375.
[cited by applicant]
Friedman et al., “Chemistry, Nutrition, and Health-Promoting Properties of Hericium ennaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and their Bioactive Compounds,” J. Agricult. Food Chem., 2015, 63:7108-7123.
[cited by applicant]
Gambaro et al., “DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in “grow-kits” seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin”, J. Pha…
[cited by applicant]
Garcia-Romeu (2015) “Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction” Current Drug Abuse Reviews. 7:3(157-164).
[cited by applicant]
Gartz (1994) “Extraction and analysis of indole derivatives from fungal biomass” Journal of Basic Microbiology. 34(1): 17-22.
[cited by applicant]
Gartz et al., “Analysis and Cultivation of Fruit Bodies and Mycelia of Psilocybe bohemica”, Biochemie und Physiologie der Pflanzen, 1989, vol. 184, pp. 337-341.
[cited by applicant]
Gartz et al., “Biotransformation of Tryptamine in Fruiting Mycelia of Psilocybe cubensis”, Planta Med., 1989, vol. 55, No. 3, pp. 249-250.
[cited by applicant]
Gartz, “Further Investigations on Pyschoactive Mushrooms of the Genera Psilocybe, Gymnopilus and Conocybe”, Ann Mus Civ Rovereto, 1992, vol. 7, pp. 265-274.
[cited by applicant]
Griffiths et al., “Psilocybin produces sbstantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial”, Journal of Psychopharmacology, vol. 30, No.…
[cited by applicant]
Griffiths, R. R., et al. “Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.” Psychopharmacology 218 (2011): 649-665.
[cited by applicant]
Grob et al., “Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer”, Arch Gen Psychiatry, 2011, vol. 68, No. 1, pp. 71-78.
[cited by applicant]
Gupta, V.K., et al. TrkB Receptor Signaling: Implications in Neurodegenerative, Psychiatric, and Proliferative Disorders, Int. J. Mol. Sci. (2013) 14(5): 10122-10142.
[cited by applicant]
Halberstadt, A.L. Recent Advances in the Neuropharmacology of Serotonergic Hallucinogens. Behav. Brain Res. (2015) 277, 99-120.
[cited by applicant]
Han, J. et al. “An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling.” F1000Research 9 (2020).
[cited by applicant]
Herraiz et al., “ß-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)”, Food and Chemical Toxicology, 2010, vol. 48, No. 3, pp. 839-845.
[cited by applicant]
Hutten et al., “Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers”, Front. Psychiatry, 2019, vol. 10, Article 672, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US20/60947 dated Mar. 17, 2021 (17 pages).
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2022/028181 dated Sep. 23, 2022 (15 pages).
[cited by applicant]
J, “My Cognition Improves Tremendously: Mushrooms & Amphetamines (Adderall XR)” Aug. 11, 2018; retrieved from Erowid. https://erowid.org/experiences/exp.php?ID=| 11984, retrieved Aug. 11, 2018.
[cited by applicant]
Jackowski, “Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer,” Brittish J. of Neurosurgery, 1995, 9:303-317.
[cited by applicant]
Julson, “16 Foods That Are High in Niacin (Vitamin B3)” Oct. 5, 2018; retrieved from WaybackMachine Internet Archive, Healthline. https://web.archive.org/web/20 | 90507 | | 3644/https://www.healthline.com/nutrition/food…
[cited by applicant]
Kaertner et al., “Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing,” Nature Sci. Rep., 2021, vol. 11, 1941.
[cited by applicant]
Kasture et al., Mucuna pruriens seeds in treatment of Parkinson's disease: pharmacological review Orient Pharm Exp Med (2013) 13:165-174 (Year: 2013).
[cited by applicant]
Kempuraj, D., et al. “COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation.” The Neuroscientist 26.5-6 (2020): 402-414.
[cited by applicant]
Khalil and Elkheir, “Dimethyltryptamine from the leaves of certain Acacia species of northern Sudan” Lloydia 38 (2): 176-177 (1975).
[cited by applicant]
Kim “PubChem in 2021: new data content and improved web interfaces” Nucleic Acids Research, 2021, vol. 49, Database issue Published online Nov. 5, 2020 (8 pages).
[cited by applicant]
Kim et al., “Hericium erinaceus (Lion's Mane) mushroom extracts inhibit metastasis of cancer cells to the lung in CT-26 colon cancer-transplanted mice”, J. Agr. Food Chem., 2013, vol. 1, No. 20, pp. 4898-4904.
[cited by applicant]
Klein, R. et al. The trkB Tyrosine Protein Kinase Is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3. Cell (2009) 66 (2): 395-403.
[cited by applicant]
Klein, R. et al. trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J. (1989) 8(12); 3701-3709.
[cited by applicant]
Koebler, A Brief History of Microdosing. Published Nov. 24, 2015, publisher Vice, URL: https://www.vice.com/en/article/begv5p5y/a-brief-history-of-microdosing (6 pages).
[cited by applicant]
Kraehenmann et al., “Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Health Volunteers”, Biological Psychiatry, vol. 78, 2015, pp. 572-581.
[cited by applicant]
Kuypers et al., “Microdosing psychedelics: More questions than answers? An overview and suggestions for future research”, J. Psychopharmacol., 2019, vol. 33, No. 9, pp. 1039-1057.
[cited by applicant]
Lake, Some Vitamins and Minerals May Reduce Alcohol Toxicity: Promising findings for certain B vitamins, vitamin C, magnesium and zinc, Jan. 29, 2019, retrieved from Psychology Today, Jan. 29, 2019, https://www.psycholo…
[cited by applicant]
Latham et al., “Development of Halogenase Enzymes for Use in Synthesis”, Chemical Reviews, vol. 118, 2018, pp. 232-269.
[cited by applicant]
Lenz et al., “Identification of omega-Methyl-4-hydroxytryptamine (norpsilocin) as a Psilocybe natural product”, J. Nat. Prod, vol. 80, No. 10, 2017, pp. 2835-2838.
[cited by applicant]
Leung, A. Y., et al. “Baeocystin and norbaeocystin: new analogs of psilocybin from Psilocybe baeocystis.” Journal of Pharmaceutical Sciences 57.10 (1968): 1667-1671.
[cited by applicant]
Licht et al., “Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases”, Hum. Psychopharmacol. Clin. Exp., 2012, vol. 27, …
[cited by applicant]
Liu, Y.-H., et al. “Group A streptococcus subcutaneous infection-induced central nervous system inflammation is attenuated by blocking peripheral TNF.” Frontiers in Microbiology 10 (2019): 265.
[cited by applicant]
Ly et al., “Psychedelics Promote Structural and Functional Neural Plasticity,” Cell Rep., 2018, 23: 3170-3182.
[cited by applicant]
Ma, et al. “Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus,” Mycology, 2010, 1:2, 92-98.
[cited by applicant]
Machado Thesis: The Frontiers of Psychedelic Therapy—Psilocybin as a New T. Universidate de Aveiro Ano 2014-2015 https://ria.ua.pt/bitstream/10773/14878/z/As%20fronteiras%20da%20pscioterapia%20psicad%C3%A9lica/pdf (Year…
[cited by applicant]
Mahmood, Z.A. “Bioactive alkaloids from fungi: Psilocybin.” Natural products: phytochemistry, botany and metabolism of alkaloids, phenolics and terpenes. Springer-Verlag, Berlin Heidelberg (2013): 523-552.
[cited by applicant]
Mattila (2001) “Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms” Journal of Agricultural and Food Chemistry. 49(5): 2343-2348.
[cited by applicant]
McCandless, Goodbye ecstasy, hello 5-Meo-DMT: new designer drugs are just a click away Psychedelics legal in US but banned in UK are openly available on the internet. The Guardian, Society, Feb. 15, 2004. https://www.th…
[cited by applicant]
Mckenna et al., “Monoamine Oxidase Inhibitors in South American Hallucinogenic Plants Parts 2: Constituents of Orally-Active Myristicaceous Hallucinogens”, Journal of Ethnopharmacology, vol. 12, 1984, pp. 179-211.
[cited by applicant]
Moir, A. T. B., et al. “The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles.” Journal of Neurochemistry 15.10 (1968): 1093-1108 (16 pages).
[cited by applicant]
Moreno, F. A., et al. “Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.” Journal of clinical Psychiatry 67.11 (2006): 1735-1740.
[cited by applicant]
Mori et al., “Improving effects of the mushroom yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double-blind placebo-controlled clinical trial”, Phytotherapy Research, 2009, vol. 23, pp. 367-372.
[cited by applicant]
Mori et al., “Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells”, Biological & pharmaceutical bulletin, 2008, vol. 31, No. 9, pp. 1727-1732.
[cited by applicant]
Nagano et al., “Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake”, Biomedical Research, 2010, vol. 31, No. 4, pp. 231-237.
[cited by applicant]
O'Mahony Carey, Report, Health Service Executive (HSE) South, Psychoactive substances: a guide to ethnobotanical plants and herbs, synthetic chemicals, compounds and products , http://hdl.handle.net/10147/112933 Issue d…
[cited by applicant]
Passie et al., “The Pharmacology of Psilocybin,” Addiction Biol., 2002, 7:357-364.
[cited by applicant]
Patel, “Recent Developments in mushrooms as anti-cancer therapeutics: a review”, Biotech, 2012, vol. 3, No. 2, pp. 1-15.
[cited by applicant]
Phan et al., “Edible and Medicinal Mushrooms: Emerging Brain Food for the Mitigation of Neurodegenerative Diseases,” J. Medicinal Foods, 2017, 20(1):1-10.
[cited by applicant]
Phan, C.-W., et al. “Hericium erinaceus (Bull.: Fr) Pers. cultivated under tropical conditions: isolation of hericenones and demonstration of NGF-mediated neurite outgrowth in PC12 cells via MEK/ERK and PI3K-Akt signali…
[cited by applicant]
Piechowska et al., “Bioactive ß-carbolines in food: A review”, Nutrients, 2019, vol. 11, No. 4, pp. 814.
[cited by applicant]
Polito et al., A systematic study of microdosing psychedelics, 2019, PLoS One, vol. 14, No. 2, e0211023.
[cited by applicant]
Prencipe, G., et al. “Nerve growth factor downregulates inflammatory response in human monocytes through TrkA.” The Journal of Immunology 192.7 (2014): 3345-3354.
[cited by applicant]
Prousky, “Vitamin B3 for Depression: Case Report and Review of the Literature”, JOM, 2010, vol. 25, No. 3, pp. 137-147.
[cited by applicant]
Psilocybin, Wikepedia, The Free Encyclopedia, 2018.
[cited by applicant]
Psilolover333, “Virgin Beauty Blossoming Consciousness Mushrooms—
[cited by applicant]
Psoodonym, “4-Ho-NMT” 2007; retrieved from Bluelight.org comment. https://bluelight.org/xf/threads/4-ho-nmt.321417/, retrieved Jun. 18, 2007.
[cited by applicant]
Rambousek et al., “The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat,” Frontiers in Behavioral Neuroscience, 2014, 8:1-7.
[cited by applicant]
Reynolds, H. et al., “Horizontal gene cluster transfer increased hallucinogenic mushroom diversity,” Evolution Letters, 2018, 2-2:88-101.
[cited by applicant]
Riba et al., “Metabolism and disposition of N, N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca”, Drug Test Anal., 2012, vol. 4, pp. 610-616.
[cited by applicant]
Sabaratnam, V., et al. “Neuronal health-can culinary and medicinal mushrooms help ?. ” Journal of traditional and complementary medicine 3.1 (2013): 62-68.
[cited by applicant]
Samoylenko, V., et al. “Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease.” Journal of ethnoph…
[cited by applicant]
Sarris et al., “Plant-Based Medicines for Anxiety Disorders, Part 2: A Reivew of Clinical Studies with Supporting Preclinical Evidence”, CNS Drugs, 2013, vol. 27, pp. 301-319.
[cited by applicant]
Saul, “Treating ADHD with Vitamin B-3 (Niacinamide)” Oct. 30, 2013; retrieved from Orthomolecular.org. http://orthomolecular.org/resources/omns/v09n23.shtml, retrieved on Oct. 30, 2013.
[cited by applicant]
Schartner et al., “Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin,” Nature Sci Reports, 2017, 7:46421.
[cited by applicant]
Sherwood et al. “Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin,” J. Nat. Prod., 2020, 83 (2): 461-467.
[cited by applicant]
Shroomery User, ILOVEMAGICMUSHROOMS, “Micro dosing for anxiety” Published Oct. 27, 2015, URL: https://www.shroomery.org/forums/showflat.php/Number/22441404 (8 pages).
[cited by applicant]
Souza, L.C., et al. “Flavonoid Chrysin prevents age-related cognitive decline via attenuation of oxidative stress and modulation of BDNF levels in aged mouse brain.” Pharmacology Biochemistry and Behavior 134 (2015): 22…
[cited by applicant]
Stamets, “Paul Statemts: Psilocybin Mushrooms and The Mycology of Consciousness”, M.A.P.S., Apr. 23, 2017, speech given, viewable on YouTube <https://www.youtube.com/watch?v=vFWxWqOFvOU>, 3 pages.
[cited by applicant]
Szigeti et al., “Self-blinding citizen science to explore psychedelic microdosing,” eLife, 2021, vol. 10, e62878.
[cited by applicant]
Teng, F., et al. “Vitamin B12 [c-lactone], a biologically inactive corrinoid compound, occurs in cultured and dried lion's mane mushroom (Hericium erinaceus) fruiting bodies.” Journal of agricultural and food chemistry …
[cited by applicant]
Third Party Submission in U.S. Appl. No. 17/669,845, dated Dec. 14, 2022 (30 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/114,381 dated Sep. 20, 2023 (35 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/115,966, dated Aug. 3, 2023 (27 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/115,966, dated Aug. 3, 2023 (38 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/498,563, dated Sep. 6, 2024 (57 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/531,052, dated Dec. 6, 2023 (49 pages).
[cited by applicant]
Third Party Submission in U.S. Appl. No. 18/531,407, dated Dec. 6, 2023 (54 pages).
[cited by applicant]
Tsai-Teng et al., “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice”, J Biomed Sci, 2016, vol. 23, No. 49, 12 pages.
[cited by applicant]
Tsujikawa et al., “Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan”, Forensic Science International, 2006, vol. 164(2-3), pp. 172-178.
[cited by applicant]
U.S. Environmental Protection Agency (EPA harmine) (Comptox Chemicals Dashboard. https://comptox.epa.gov/dashboard/ chemical/details/DTXSI D30196066, Harmine, accessed Jul. 2023). (Year: 2023).
[cited by applicant]
U.S. Environmental Protection Agency (EPA Norharmine) (Comptox Chemicals Dashboard. https://comptox.epa.gov/dashboard/ chemical/details/DTXSI D30431161, 7-Methoxy-9H-pyrido[3,4-b]indole) (Year: 2023).
[cited by applicant]
Walpole, S.C. et al. The weight of nations: an estimation of adult human biomass. BMC Public Health (2012), 12, 439.
[cited by applicant]
West, Solid State Chemistry and Its Applications, John Wiley & Sons, 1984 (3 pages).
[cited by applicant]
Wieczorek (2015) “Chapter 5—Bioactive Alkaloids of Hallucinogenic Mushrooms” Studies in Natural Products Chemistry. 46: 133-168.
[cited by applicant]
Wilcox (2014) “Psilocybin and Obsessive Compulsive Disorder” Journal of Psychoactive Drugs. 46:5(393-395).
[cited by applicant]
Wolff, Burger's Medicinal Chemistry and Drug Discovery, vol. 1, Principles and Practice, John Wiley & Sons, New York, 1997 (4 pages).
[cited by applicant]
Wronska et al., “Harman and norharman, metabolites of entomopathogenic fungus Conidiobolus coronatus (Entomophthorales), disorganized development of Galleria mellonella (Lepidoptera) and affect serotonin-regulating enzy…
[cited by applicant]
Yang et al., “Anti-inflammatory principles from Cordyceps sinensis”, Journal of Natural Products, 2011, vol. 74, No. 9, pp. 1996-2000.
[cited by applicant]
Yang et al., “Hericium erinaceus Mycelium Exerts Neuroprotective Effect in Parkinson's Disease-in vitro and in vivo Models”, J Drug Res Dev, 2020, vol. 6, Issue 1, pp. 1-6.
[cited by applicant]
Zhang et al., “Erinacerins, Novel Glioma Inhibitors from Hericium erinaceus, Induce Apoptosis of U87 Cells through Bax/Capase-2 Pathway,” Anticancer Agents Med. Chem., 2020, 20(17): 2082-2088 (preprint).
[cited by applicant]
Zhang, C., et al. “Somatostatin-positive GABAergic interneuron: new targets for depression.” Molecular Psychiatry 22.6 (2017): 790-791.
[cited by applicant]
Zhang, C.-C., et al. “Chemical constituents from Hericium erinaceus promote neuronal survival and potentiate neurite outgrowth via the TrkA/Erk1/2 pathway.” International journal of molecular sciences 18.8 (2017): 1659.
[cited by applicant]